Table 4. Relation of ALK5-FL, ALK5-ICD, pSMAD2/3 and PAI-1 protein levels to categorized clinicopathological parameters in ccRCC VHL-High.
Parameter | ALK5-FL | ALK5-ICD | pSMAD2/3 | PAI-1 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
na | Mean Rank | P-Valueb | na | Mean Rank | P-Valueb | na | Mean Rank | P-Valueb | na | Mean Rank | P-Valueb | |
Grade | ||||||||||||
I (I+II) | 34 | 35.78 | 34 | 32.24 | 34 | 33.47 | 34 | 30.13 | ||||
0.911 | 0.206 | 0.416 | 0.032 | |||||||||
II (III+IV) | 36 | 35.24 | 36 | 38.49 | 36 | 37.42 | 36 | 40.57 | ||||
TNM Stage | ||||||||||||
Early Stage (I+II) | 37 | 34.12 | 37 | 30.11 | 37 | 35.20 | 37 | 29.46 | ||||
0.548 | 0.019 | 0.897 | 0.009 | |||||||||
Advanced Stage (III+IV) | 33 | 37.05 | 33 | 41.55 | 33 | 35.83 | 33 | 42.27 | ||||
Tumor size (mm) | ||||||||||||
<70 | 29 | 38.47 | 29 | 37.62 | 29 | 36.03 | 29 | 36 | ||||
0.305 | 0.463 | 0.853 | 0.863 | |||||||||
>70 | 41 | 33.40 | 41 | 34 | 41 | 35.12 | 41 | 35.15 |
a Number of patients.
b Groups were compared using Mann-Whitney U test (significant at P<0.05).